Pacira BioSciences (PCRX) Expected to Announce Earnings on Thursday

Pacira BioSciences (NASDAQ:PCRX) is expected to be posting its Q1 2026 results after the market closes on Thursday, April 30th. Analysts expect Pacira BioSciences to post earnings of $0.61 per share and revenue of $173.5270 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Thursday, April 30, 2026 at 4:30 PM ET.

Pacira BioSciences (NASDAQ:PCRX) last posted its earnings results on Thursday, February 26th. The company reported $0.57 EPS for the quarter, missing analysts’ consensus estimates of $0.85 by ($0.28). The firm had revenue of $196.87 million for the quarter, compared to the consensus estimate of $201.93 million. Pacira BioSciences had a net margin of 0.97% and a return on equity of 10.39%. The firm’s revenue was up 5.1% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.91 earnings per share. On average, analysts expect Pacira BioSciences to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Pacira BioSciences Price Performance

Shares of NASDAQ PCRX traded down $0.22 during midday trading on Wednesday, reaching $25.19. 49,808 shares of the stock traded hands, compared to its average volume of 798,580. The company has a debt-to-equity ratio of 0.54, a current ratio of 4.54 and a quick ratio of 3.28. The stock has a market capitalization of $1.02 billion, a PE ratio of 168.23 and a beta of 0.19. Pacira BioSciences has a one year low of $18.80 and a one year high of $27.64. The company’s 50 day moving average is $23.22 and its 200 day moving average is $23.11.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the company. Needham & Company LLC reiterated a “buy” rating and set a $30.00 target price on shares of Pacira BioSciences in a research report on Friday, January 9th. HC Wainwright restated a “buy” rating and set a $38.00 price target on shares of Pacira BioSciences in a report on Friday, January 9th. Zacks Research upgraded Pacira BioSciences from a “strong sell” rating to a “hold” rating in a report on Tuesday, April 7th. Wall Street Zen downgraded shares of Pacira BioSciences from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 28th. Finally, Barclays reduced their target price on shares of Pacira BioSciences from $27.00 to $25.00 and set an “equal weight” rating on the stock in a research note on Thursday, March 26th. Three investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $30.25.

Insider Activity

In other Pacira BioSciences news, CFO Shawn Cross sold 12,941 shares of the company’s stock in a transaction on Thursday, April 23rd. The stock was sold at an average price of $25.16, for a total value of $325,595.56. Following the transaction, the chief financial officer owned 105,341 shares of the company’s stock, valued at $2,650,379.56. This represents a 10.94% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Jonathan Slonin sold 3,261 shares of the company’s stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $22.82, for a total value of $74,416.02. Following the completion of the transaction, the insider directly owned 223,640 shares in the company, valued at $5,103,464.80. This trade represents a 1.44% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 32,261 shares of company stock valued at $785,850. 6.40% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Pacira BioSciences

Hedge funds have recently bought and sold shares of the business. Inspire Investing LLC grew its position in Pacira BioSciences by 3.2% in the 4th quarter. Inspire Investing LLC now owns 17,958 shares of the company’s stock valued at $465,000 after acquiring an additional 556 shares during the last quarter. Natixis Advisors LLC grew its position in Pacira BioSciences by 22.0% in the 3rd quarter. Natixis Advisors LLC now owns 16,112 shares of the company’s stock valued at $415,000 after acquiring an additional 2,905 shares during the last quarter. Fox Run Management L.L.C. bought a new position in Pacira BioSciences in the 4th quarter valued at $365,000. Quantinno Capital Management LP bought a new position in Pacira BioSciences in the 2nd quarter valued at $310,000. Finally, Rafferty Asset Management LLC bought a new position in Pacira BioSciences in the 4th quarter valued at $240,000. Institutional investors own 99.73% of the company’s stock.

Pacira BioSciences Company Profile

Pacira BioSciences, Inc is a specialty pharmaceutical company focused on developing and commercializing non-opioid, non-addictive pain management and regenerative health solutions. The company’s flagship product, EXPAREL, is a bupivacaine liposome injectable suspension designed to provide long-lasting postsurgical analgesia. EXPAREL is used by clinicians across a broad range of surgical procedures to reduce reliance on opioid medications and to help manage acute postoperative pain.

In addition to its marketed offering, Pacira maintains an active pipeline of investigational products aimed at addressing unmet needs in pain management and inflammation control.